{"id":"NCT02506868","sponsor":"Biocad","briefTitle":"Safety and Efficacy Study of BCD-066 Compared to Aranesp® for Anemia Treatment in Chronic Kidney Disease Patients","officialTitle":"Multicenter Double-blind Randomized Parallel Comparative Study of Efficacy and Safety of BCD-066 (CJSC BIOCAD, Russia) and Aranesp (Amgen Europe B.V., Netherlands) in Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-08-08","primaryCompletion":"2017-01-08","completion":"2017-12-21","firstPosted":"2015-07-23","resultsPosted":"2019-05-30","lastUpdate":"2020-05-07"},"enrollment":196,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Kidney Disease","End Stage Renal Failure on Dialysis","Anemia"],"interventions":[{"type":"DRUG","name":"Darbepoetin alfa","otherNames":["Aranesp","BCD-066"]}],"arms":[{"label":"BCD-066","type":"EXPERIMENTAL"},{"label":"Aranesp","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of the study is to prove equivalence of efficacy and safety of BCD-066 and Aranesp® in treatment of anemia in end-stage chronic kidney disease patients on dialysis.","primaryOutcome":{"measure":"Change in Hemoglobin (Hb) Concentration From Baseline to the Evaluation Period","timeFrame":"Baseline - measurements on Screening (weeks -4 - 0) and on day 1; Evaluation period - weekly measures on weeks 21 to 24","effectByArm":[{"arm":"BCD-066","deltaMin":4.695,"sd":10.941},{"arm":"Aranesp","deltaMin":4.641,"sd":8.987}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":11,"exclusionCount":31},"locations":{"siteCount":30,"countries":["Russia"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":19,"n":98},"commonTop":["hyperkalemia","Increased blood pressure","lymphopenia","hyperglycemia","C-reactive protein increased"]}}